Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study - Richardson, Paul G.; Raab, Marc-Steffen (The lancet. Haematology, 2015)
Gesehen am 28.07.2016